| Autor: |
Bonnett, Chris G. |
| Předmět: |
|
| Zdroj: |
Canadian Medical Association Journal (CMAJ); 10/1/2024, Vol. 196 Issue 32, pE1124-E1124, 1p |
| Abstrakt: |
The article discusses the role of private insurance in the proposed Pharmacare Act in Canada. The authors argue against a publicly funded single-payer (PSP) drug plan, stating that it would increase costs and complexity and reduce equity. They suggest that purported cost savings with a PSP plan are uncertain and difficult to verify. The authors propose improving both public and private plans, implementing consistent eligibility rules and access to high-cost drugs, and focusing on health technology assessment and price negotiations. They argue that private insurance is essential for the success of pharmacare and that a mixed-payer model with strong regulation and governance could be a more pragmatic approach. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
